全文获取类型
收费全文 | 1643254篇 |
免费 | 122692篇 |
国内免费 | 3900篇 |
学科分类
医药卫生 | 1769846篇 |
出版年
2018年 | 15356篇 |
2015年 | 15391篇 |
2014年 | 22053篇 |
2013年 | 33965篇 |
2012年 | 45356篇 |
2011年 | 48047篇 |
2010年 | 28671篇 |
2009年 | 27172篇 |
2008年 | 45808篇 |
2007年 | 49324篇 |
2006年 | 49253篇 |
2005年 | 48556篇 |
2004年 | 46975篇 |
2003年 | 45471篇 |
2002年 | 44188篇 |
2001年 | 71079篇 |
2000年 | 72857篇 |
1999年 | 61985篇 |
1998年 | 18001篇 |
1997年 | 16500篇 |
1996年 | 16247篇 |
1995年 | 15300篇 |
1994年 | 14634篇 |
1993年 | 13742篇 |
1992年 | 50577篇 |
1991年 | 48974篇 |
1990年 | 48004篇 |
1989年 | 46276篇 |
1988年 | 43218篇 |
1987年 | 42555篇 |
1986年 | 40684篇 |
1985年 | 39047篇 |
1984年 | 29771篇 |
1983年 | 25421篇 |
1982年 | 15768篇 |
1981年 | 14200篇 |
1980年 | 13433篇 |
1979年 | 29047篇 |
1978年 | 20725篇 |
1977年 | 17466篇 |
1976年 | 16306篇 |
1975年 | 17771篇 |
1974年 | 21720篇 |
1973年 | 20788篇 |
1972年 | 19761篇 |
1971年 | 18285篇 |
1970年 | 17527篇 |
1969年 | 16704篇 |
1968年 | 15508篇 |
1967年 | 14282篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Toidi Adekambi Chris C. Ibegbu Stephanie Cagle Ameeta S. Kalokhe Yun F. Wang Yijuan Hu Cheryl L. Day Susan M. Ray Jyothi Rengarajan 《The Journal of clinical investigation》2015,125(5):1827-1838
BACKGROUND. The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient’s sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.METHODS. Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment.RESULTS. Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment.CONCLUSION. We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure.TRIAL REGISTRATION. Registration is not required for observational studies.FUNDING. This study was funded by Emory University, the NIH, and the Yerkes National Primate Center. 相似文献
42.
Thomas W. McDade Alexander V. Georgiev Christopher W. Kuzawa 《Evolution, Medicine, and Public Health》2016,2016(1):1-16
Immune defenses provide resistance against infectious disease that is critical to survival. But immune defenses are costly, and limited resources allocated to immunity are not available for other physiological or developmental processes. We propose a framework for explaining variation in patterns of investment in two important subsystems of anti-pathogen defense: innate (non-specific) and acquired (specific) immunity. The developmental costs of acquired immunity are high, but the costs of maintenance and activation are relatively low. Innate immunity imposes lower upfront developmental costs, but higher operating costs. Innate defenses are mobilized quickly and are effective against novel pathogens. Acquired responses are less effective against novel exposures, but more effective against secondary exposures due to immunological memory. Based on their distinct profiles of costs and effectiveness, we propose that the balance of investment in innate versus acquired immunity is variable, and that this balance is optimized in response to local ecological conditions early in development. Nutritional abundance, high pathogen exposure and low signals of extrinsic mortality risk during sensitive periods of immune development should all favor relatively higher levels of investment in acquired immunity. Undernutrition, low pathogen exposure, and high mortality risk should favor innate immune defenses. The hypothesis provides a framework for organizing prior empirical research on the impact of developmental environments on innate and acquired immunity, and suggests promising directions for future research in human ecological immunology. 相似文献
43.
More than just crushing: a prospective pre‐post intervention study to reduce drug preparation errors in patients with feeding tubes 下载免费PDF全文
44.
45.
46.
47.
48.
49.